WO2021103777A1 - Agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à une rhinite allergique chez les enfants et adolescents - Google Patents

Agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à une rhinite allergique chez les enfants et adolescents Download PDF

Info

Publication number
WO2021103777A1
WO2021103777A1 PCT/CN2020/116449 CN2020116449W WO2021103777A1 WO 2021103777 A1 WO2021103777 A1 WO 2021103777A1 CN 2020116449 W CN2020116449 W CN 2020116449W WO 2021103777 A1 WO2021103777 A1 WO 2021103777A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
volatile oil
children
chinese medicine
allergic rhinitis
Prior art date
Application number
PCT/CN2020/116449
Other languages
English (en)
Chinese (zh)
Inventor
赵天抒
李华京
王静
Original Assignee
垒途智能教科技术研究院江苏有限公司
南京中垒科技发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 垒途智能教科技术研究院江苏有限公司, 南京中垒科技发展有限公司 filed Critical 垒途智能教科技术研究院江苏有限公司
Publication of WO2021103777A1 publication Critical patent/WO2021103777A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • A61K36/835—Aquilaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Definitions

  • the invention specifically relates to a spray used for the prevention and treatment of allergic asthma combined with allergic rhinitis in children and adolescents.
  • Allergic rhinitis asthma (Combined Allergic Rhinitis and Asthma Syndrome.CARAS) refers to the simultaneous occurrence of clinical or subclinical upper respiratory tract allergy (allergic rhinitis) and lower respiratory tract allergic symptoms (asthma), both of which often coexist at the same time.
  • the immunological and pathological changes of the upper and lower respiratory tracts of allergic rhinitis and asthma are allergic inflammation of the nasal mucosa and bronchial mucosa, respectively. Inflammation of nasal mucosa and bronchial mucosa is very similar in terms of pathogenic factors, genetic changes, local pathological changes, abnormal immune function and pathogenesis.
  • the existing drugs are mainly treated with nasal hormones, oral or nasal antihistamines, etc., but the long-term effect is not very satisfactory, and the side effects of long-term use are relatively large.
  • the purpose of the present invention is to aim at the pathogenesis characteristics of children and adolescents with allergic asthma combined with allergic rhinitis, provide a portable and easy to use, can effectively improve the physical state of children with allergies, and can safely and effectively treat children with allergies Sprays for rhinitis and asthma.
  • a spray for the prevention and treatment of children and adolescents with allergic asthma and allergic rhinitis which includes pharmaceutical ingredients and auxiliary materials;
  • the pharmaceutical ingredients include volatile oil and Chinese medicine extracts:
  • the volatile oil is made from the following raw materials:
  • Annona seed volatile oil tangerine peel volatile oil, agarwood volatile oil, perilla volatile oil, honeysuckle volatile oil, borneol;
  • the Chinese medicine extract is prepared from the following raw materials:
  • the above-mentioned spray for the prevention and treatment of allergic asthma combined with allergic rhinitis in children and adolescents which includes pharmaceutical ingredients and auxiliary materials;
  • the pharmaceutical ingredients include volatile oil and Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
  • the Chinese medicine extract is prepared from the following raw materials:
  • the above-mentioned spray for the prevention and treatment of allergic asthma combined with allergic rhinitis in children and adolescents which includes pharmaceutical ingredients and auxiliary materials;
  • the pharmaceutical ingredients include volatile oil and Chinese medicine extracts: the volatile oil is prepared from the following raw materials:
  • the Chinese medicine extract is prepared from the following raw materials:
  • auxiliary materials include ethanol, 1,3-propanediol, and purified water.
  • the volume ratio of 1,3-propanediol and purified water is 1-2:1-2:10.
  • the above-mentioned spray for the prevention and treatment of allergic asthma combined with allergic rhinitis in children and adolescents wherein the weight percentage of the pharmaceutical ingredients is 5-15%.
  • the spray for the prevention and treatment of allergic asthma in children and adolescents combined with allergic rhinitis according to the present invention, the essential oil of annona seed, the essential oil of tangerine peel, the essential oil of agarwood, the essential oil of perilla and the essential oil of honeysuckle all adopt steam distillation or super Extracted by critical extraction method.
  • extracting by steam distillation add 8 to 10 times the amount of water, use steam distillation device, extract for 2 hours, and collect the volatile oil.
  • the preparation method of the traditional Chinese medicine extract includes the following steps:
  • the preparation method of traditional Chinese medicine extract includes the following steps:
  • the invention uses white mustard seeds after long-term tests, which are pungent, warm and non-toxic. Go nose. Mainly eliminates kidney evil qi, helps nine orifices, improves eyes and ears, warms the lungs, eliminates phlegm and promotes qi. It is used for cold phlegm, asthma and cough, chest pain, phlegm stagnation in the meridian, numbness and pain of joints, phlegm dampness flow, swollen syringe and poison.
  • Chrysanthemum belongs to lung and liver meridian. It has the effects of dispelling wind-heat, calming the liver and improving eyesight, clearing away heat and detoxification. Indications: wind-heat and cold, fever, headache, dim eyesight, clearing wind and heat, clearing liver and fire, clearing heat and detoxification, etc.
  • Vitex quinquefolia has a pungent, bitter taste and slightly cold in nature. Return to lung, bladder, liver meridian. Frivolity Shengsan This product can disperse wind, clear away heat from slight cold, frivolity ascends, mainly disperses the evil of the head and face, has the effect of dispelling wind and relieving pain, and is used to treat exogenous wind-heat, headache and dizziness.
  • the invention is innovatively added with Maoyan berry tea, which is a vine tea variety that grows and multiplies in the specific geographical and climatic environment of Zhangjiajie, and belongs to a deciduous vine (Vitis).
  • the plant contains a natural plant cream
  • the active ingredient is mainly flavonoids, containing flavonoid crude protein 12.8 ⁇ 13.8, the average content of total flavonoids is ⁇ 6%, the highest detected content is 9.37%, which is all found so far Plants have the highest content of flavonoids, so they are called the “king of flavonoids” (flavonoids are known as "vascular scavengers” in medical circles, and they are the new favorite for the prevention of cardiovascular and cerebrovascular diseases).
  • the main flavonoids of Maoyan Berry Tea, dihydroxymycin has anti-bacterial and anti-inflammatory properties, clearing away heat and detoxification, relieving pain, reducing swelling, moistening throat and relieving cough, Improve human immunity, anti-allergic and other functions.
  • Pueraria lobata sweet, pungent, and cold. It has the functions of relieving muscles and reducing fever, removing rash, producing body fluid to quench thirst, and promoting Yang to stop diarrhea. It is often used for symptoms of fever, strong nape and back pain, impervious measles, thirst due to fever, yin deficiency to reduce thirst, heat diarrhea and heat dysentery, spleen deficiency and diarrhea.
  • Scutellaria baicalensis is used for heat-clearing, detoxifying and dampness, mainly treating febrile diseases, for children's body heat, used for damp heat, chest tightness, thirst and unwilling to drink, etc.
  • Xanthium is pungent, bitter, warm in nature, and poisonous. Return to the lung meridian. It has the functions of dispersing wind, removing dampness, and relieving pain. Indications: dispersing wind-cold, clearing nose and orifices, and dispelling rheumatism.
  • Ephedra mainly contains ephedrine, which is warm in nature, pungent in taste and slightly bitter. It has the effects of sweating and dispelling cold, promoting lung and asthma, diuresis and swelling. It can treat cold, cold, chest tightness, cough, wind swelling, bronchial asthma and other diseases.
  • Polygonum cuspidatum has a slightly bitter taste, slightly cold in nature, and belongs to the liver, gallbladder and lung meridians. It has the German effect of eliminating dampness and relieving yellow, clearing heat and detoxification, dispelling blood stasis and relieving pain, relieving cough and resolving phlegm. It can be used for lung-heat cough, rheumatism arthralgia, carbuncle swelling and sore toxin, water and fire burns, amenorrhea, symptom and rash injuries.
  • Salvia miltiorrhiza contains tanshinone, which is a strong meridian, which has the equivalent functions of removing blood stasis, regenerating new life, and promoting blood circulation.
  • the addition of salvia in the present invention can help promote blood circulation and has a better auxiliary effect on lung asthma and allergies.
  • the present invention adopts the volatile oil components of the preferred composition and the preferred traditional Chinese medicine extract components, and has the functions of dispelling wind and resuscitation, relieving the lungs and relieving asthma, dispelling wind, and expelling evil spirits.
  • Detoxification, cooling blood and promoting blood circulation, etc. can relieve external evils, clear the lung orifices, and achieve the effect of clearing the nose orifices. It has a good anti-allergic asthma and rhinitis effect, and through volatile components and traditional Chinese medicine extracts Nasal spray is easier to absorb until the capillaries of the nose and lungs, and the effect is quicker.
  • the volatile oil of annona seed, the volatile oil of tangerine peel, the volatile oil of agarwood, the volatile oil of perilla, and the volatile oil of honeysuckle are all obtained by the following methods:
  • a spray for the prevention and treatment of children and adolescents with allergic asthma combined with allergic rhinitis which includes pharmaceutical ingredients and auxiliary materials (ethanol:1,3-propanediol:purified water volume ratio 1:2:10); the pharmaceutical ingredients account for The weight percentage of the volatile oil is 8%; the pharmaceutical ingredients are made of volatile oil and traditional Chinese medicine extracts: the volatile oil is obtained by combining the following components:
  • Annona seed volatile oil 9g tangerine peel volatile oil 6g, agarwood volatile oil 3g, perilla volatile oil 6g, honeysuckle volatile oil 6g, and borneol 1g;
  • the Chinese medicine extract is prepared from the following raw materials:
  • the described Chinese medicine extracts are all prepared by the following methods:
  • the weight ratio take 10g of white mustard seed, 18g of chrysanthemum, 10g of vitex, 15g of Maoyanberry tea, 15g of kudzu root, 12g of scutellaria, 15g of dense ephedra, 6g of fried cocklebur, 6g of knotweed and 6g of salvia.
  • a spray for the prevention and treatment of children and adolescents with allergic asthma combined with allergic rhinitis which includes pharmaceutical ingredients and auxiliary materials (ethanol:1,3-propanediol:purified water volume ratio 1:2:10); the pharmaceutical ingredients account for The weight percentage of the volatile oil is 8%; the pharmaceutical ingredients are made of volatile oil and traditional Chinese medicine extracts: the volatile oil is obtained by combining the following components:
  • Annona seed volatile oil 3g tangerine peel volatile oil 6g, agarwood volatile oil 1g, perilla volatile oil 6g, honeysuckle volatile oil 6g, borneol 1g;
  • the Chinese medicine extract is prepared from the following raw materials:
  • the described Chinese medicine extracts are all prepared by the following methods:
  • the weight ratio take 5g of white mustard seed, 18g of chrysanthemum, 10g of vitex, Maoyanberry tea 5g, kudzu root 15g, scutellaria 12g, dense ephedra 15g, fried cocklebur 6g, polygonum cuspidatum 6g and salvia 3g, for the first time Adding 10 times the total weight of the medicinal materials with water, decocting and extracting for 2 hours, adding 8 times the total weight of the medicinal materials for the second time, decocting and extracting for 1 hour, combining the extracts, and concentrating to obtain the extract.
  • a spray for the prevention and treatment of children and adolescents with allergic asthma combined with allergic rhinitis which includes pharmaceutical ingredients and auxiliary materials (ethanol:1,3-propanediol:purified water volume ratio 1:2:10); the pharmaceutical ingredients account for The weight percentage of is 8%; the pharmaceutical ingredient is volatile oil: the volatile oil is obtained by combining the following components:
  • Annona seed volatile oil 9g tangerine peel volatile oil 6g, agarwood volatile oil 2g, perilla volatile oil 6g, honeysuckle volatile oil 6g, and borneol 1g.
  • a spray for the prevention and treatment of children and adolescents with allergic asthma combined with allergic rhinitis which includes pharmaceutical ingredients and auxiliary materials (ethanol:1,3-propanediol:purified water volume ratio 1:2:10); the pharmaceutical ingredients account for The weight percentage is 8%; the Chinese medicine extract is made from the following raw materials:
  • the described Chinese medicine extracts are all prepared by the following methods:
  • the weight ratio take 10g of white mustard seed, 18g of chrysanthemum, 10g of vitex, 15g of Maoyanberry tea, 15g of kudzu root, 12g of scutellaria, 15g of dense ephedra, 6g of fried cocklebur, 6g of knotweed and 6g of salvia.
  • test cases for allergic asthma combined with allergic rhinitis refer to the diagnostic criteria for allergic asthma and allergic rhinitis (diagnostic criteria for allergic asthma: refer to the "Guidelines for the Prevention and Treatment of Bronchial Asthma" formulated by the Asthma Group of the Respiratory Branch of the Chinese Medical Association (2008) "Selected 40 patients with allergic asthma and allergic rhinitis randomly divided into the treatment group of Example 1, Example 2 and the control group 1, the control group 2 control group. 40 patients with allergic asthma and allergic rhinitis, 22 males and females There were 18 cases, aged 3-15 years, with an average of 8 ⁇ 1.2 years old. There was no statistical difference in gender, age, and course of disease between the two groups.
  • Treatment method The treatment group was sprayed with the sprays of Example 1 and Example 2 every day, 3 times a day, 2 ml each time.
  • the control group 1 and the control group 2 were sprayed with the sprays of the control group 1 and the control group 2 respectively every day, 3 times a day, 2 ml each time.
  • the treatment effect was evaluated after 3 months of medication.
  • 1Asthma control score 25 points for complete asthma control, 20-24 points for good asthma control, and less than 20 points for uncontrolled asthma.
  • 2Rhinitis symptom scoring standard A. Refer to the allergic rhinitis scoring standard in "Allergic Rhinitis Handling Pocket Reference 2009" to evaluate the patient's symptoms.
  • RQLQ score scale score before and after treatment.
  • 4Evaluation index of the curative effect of allergic rhinitis the improvement rate is calculated by [(total score before treatment-total score after treatment)/total score before treatment]*100%, among which, markedly effective ⁇ 51%; effective ⁇ 50%, ⁇ 21%; Invalid ⁇ 20%.
  • 5Total effective rate Effective: Asthma score is 20 points or more, meanwhile, allergic rhinitis curative effect evaluation index ⁇ 51%; improvement: Asthma score is 20-24 points, and allergic rhinitis curative effect evaluation index ⁇ 50%, ⁇ 21% ; Invalid: Asthma ⁇ 20 points, meanwhile, the evaluation index of curative effect of allergic rhinitis ⁇ 20%.
  • Results The collected data is statistically analyzed using SPSS 18.0 software. The results of asthma control score and rhinitis symptom score are shown in Table 1, and the results of RQLQ score and serum total IgE index are shown in Table 2. The results show that Example 1 and Example 2 of the present invention have better efficacy in treating asthma and rhinitis compared to Examples 1 and 2 of the control group.
  • the effective rate of Example 1 of the present invention is 90%, and the effective rate of the treatment group of Example 2 is 80%, which is significantly higher than that of the control group 1 (effective rate of 20%) and control group 2 (effective rate of 30%).
  • the specific results are shown in Table 3. .
  • the spray provided by the present invention has a good therapeutic effect on allergic asthma combined with allergic rhinitis
  • the present invention is effective in reducing the volatile oil of annon-apple seeds, scented volatile oil, and white mustard seeds.
  • the content of Cranberry and Maoyanberry tea the therapeutic effect is reduced.
  • the spray dose is the same, when compared with a single volatile oil component or a single Chinese medicine extract component, when the volatile oil and the Chinese medicine extract are used together, it shows a more significant effect on the treatment of allergic asthma and allergic rhinitis, indicating that each component Supplement each other and play a synergistic role.
  • IL-5 and IL-13 kits were purchased from Hangzhou Lianke Biotechnology Co., Ltd.
  • Test drugs Example 1, Example 2, Control Example 1 and Control Example 2, which were administered by spray;
  • mice 4-6 weeks old, female, SPF grade, provided by Qinglongshan Animal Breeding Farm, Jiangning District, Nanjing.
  • mice were randomly divided into 6 groups, normal group, model group, example 1, example 2, control group 1, and control group 2.
  • model group, example 1, example 2, control group 1 and control group 2 were intraperitoneally injected with 0.4ml OVA sensitizing solution (from OVA 2g, aluminum hydroxide gel 20ml, physiological saline 20ml on day 0 and day 7, respectively).
  • OVA sensitizing solution from OVA 2g, aluminum hydroxide gel 20ml, physiological saline 20ml on day 0 and day 7, respectively.
  • the normal group was intraperitoneally injected with the same amount of saline.
  • the 5% OVA solution was sprayed and inhaled for 30 minutes for excitation, and continuously sprayed for 5 days, once a day, for 30 minutes each time.
  • the mice in the normal group were atomized with the same amount of normal saline.
  • Example 1 Example 2, the control group 1 and the control group 2 were all administered by atomized spray, 2 ml each time, 3 times a day, and sprayed continuously for 7 days.
  • Diagnosis Western medicine: Allergic rhinitis with asthma
  • Example 1 Use the spray of Example 1 to spray, 3 times a day, 2 mL each time.
  • the patient After 4 weeks of continuous spray treatment, the patient will be re-diagnosed for nasal itching, nasal congestion, night cough and asthma, better than before, good appetite, bowel movements, and the tongue is dull and red.
  • Diagnosis Western medicine: Allergic rhinitis combined with asthma.
  • Example 1 Use the spray of Example 1 to spray, 3 times a day, 2 mL each time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Il est divulgué un agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à la rhinite allergique chez les enfants et les adolescents. L'agent de pulvérisation comprend des ingrédients pharmaceutiques et des matériaux auxiliaires. Les ingrédients pharmaceutiques comprennent des huiles volatiles et un extrait de médecine traditionnelle chinoise, les huiles volatiles comprenant de l'huile volatile de graines d'Annona squamosa, de l'huile volatile de Citri reticulatae pericarpium, de l'huile volatile d'Aquilariae lignum resinatum, de l'huile volatile de Perillae fructus, de l'huile volatile de Lonicerae japonicae flos et du Borneolum syntheticum ; et l'extrait de médecine traditionnelle chinoise est préparé à partir de Sinapis alba, de Chrysanthemi flos, de Viticis fructus, d'Ampelopsis grossedentata, de racine de Puerariae lobatae, de racine de Scutellariae, de préparation d'herbe d'Ephedrae, de Xanthii fructus frit, de rhizome et de racine de Polygoni cuspidati et de rhizome et de racine de Salviae miltiorrhizae.
PCT/CN2020/116449 2019-11-25 2020-09-21 Agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à une rhinite allergique chez les enfants et adolescents WO2021103777A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911167225.5A CN110917271A (zh) 2019-11-25 2019-11-25 一种用于儿童、青少年过敏性哮喘合并过敏性鼻炎防治的喷雾剂
CN201911167225.5 2019-11-25

Publications (1)

Publication Number Publication Date
WO2021103777A1 true WO2021103777A1 (fr) 2021-06-03

Family

ID=69851014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/116449 WO2021103777A1 (fr) 2019-11-25 2020-09-21 Agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à une rhinite allergique chez les enfants et adolescents

Country Status (2)

Country Link
CN (1) CN110917271A (fr)
WO (1) WO2021103777A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917271A (zh) * 2019-11-25 2020-03-27 垒途智能教科技术研究院江苏有限公司 一种用于儿童、青少年过敏性哮喘合并过敏性鼻炎防治的喷雾剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1806815A (zh) * 2005-01-17 2006-07-26 佛山德众药业有限公司 治疗鼻科疾病的药物组合物及其制备方法
CN101612280A (zh) * 2009-07-16 2009-12-30 杨立光 一种用于治疗鼻炎鼻窦炎的膏剂
CN108114040A (zh) * 2018-01-16 2018-06-05 成都市飞龙水处理技术研究所青白江第分所 一种用于治疗过敏性鼻炎的胶囊剂药物及其制备方法
CN110917271A (zh) * 2019-11-25 2020-03-27 垒途智能教科技术研究院江苏有限公司 一种用于儿童、青少年过敏性哮喘合并过敏性鼻炎防治的喷雾剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216574A1 (en) * 2012-02-20 2013-08-22 James Liu Kit providing multiple unmet therapeutic effects
CN104548024A (zh) * 2015-01-06 2015-04-29 山东省中医药研究院 一种治疗过敏性鼻炎-哮喘综合征的外用药物
CN107753664B (zh) * 2017-12-01 2020-11-06 大连大学 一种治疗过敏性鼻炎的中药组合物及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1806815A (zh) * 2005-01-17 2006-07-26 佛山德众药业有限公司 治疗鼻科疾病的药物组合物及其制备方法
CN101612280A (zh) * 2009-07-16 2009-12-30 杨立光 一种用于治疗鼻炎鼻窦炎的膏剂
CN108114040A (zh) * 2018-01-16 2018-06-05 成都市飞龙水处理技术研究所青白江第分所 一种用于治疗过敏性鼻炎的胶囊剂药物及其制备方法
CN110917271A (zh) * 2019-11-25 2020-03-27 垒途智能教科技术研究院江苏有限公司 一种用于儿童、青少年过敏性哮喘合并过敏性鼻炎防治的喷雾剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG XIANXIANG: "Observation on 32 Cases of Infantile Asthma Treated by Self-made "Erhuang Danlong Decoction" Nebulized Inhalation", SHANDONG MEDICAL JOURNAL, vol. 41, no. 18, 25 September 2001 (2001-09-25), pages 72 - 72, XP055816677 *
LI JINCHENG: "Preparation and clinical application of Biyanqing nose drops", CHINESE JOURNAL OF HOSPITAL PHARMACY, vol. 22, no. 4, 28 April 2002 (2002-04-28), pages 247 - 248, XP055816689, ISSN: 1001-5213 *
YANG XIE: "Preparation and clinical application of Yinhuang rhinitis drops", CHINESE TRADITIONAL PATENT MEDICINE, vol. 26, no. 12, 25 December 2004 (2004-12-25), pages 1093 - 1093, XP055816683, ISSN: 1001-1528 *

Also Published As

Publication number Publication date
CN110917271A (zh) 2020-03-27

Similar Documents

Publication Publication Date Title
CN101181393A (zh) 治疗感冒的中药制剂及其生产方法
CN104940485A (zh) 一种治疗小儿哮喘的中药组合物及其制备方法
WO2021103777A1 (fr) Agent de pulvérisation pour la prévention et le traitement de l'asthme allergique combiné à une rhinite allergique chez les enfants et adolescents
CN102085346A (zh) 一种治疗慢性阻塞性肺病的中药组合物
CN104353029A (zh) 一种润肺橘红膏及其制备方法
CN108686058A (zh) 七窍通鼻炎喷剂及其制备方法
CN100353985C (zh) 止咳喘与润肺的药物及其制备方法
WO2021251617A1 (fr) Composition de médicament brut pour soulager ou traiter la rhinite, solution de pharmacoponcture de médecine orientale comprenant celle-ci, injection la comprenant, et procédé de pharmacoponcture l'utilisant
CN102641428B (zh) 一种预防上呼吸道感染的药茶
CN102698073B (zh) 一种治疗过敏性鼻炎的中药浸膏
CN102657782B (zh) 一种预防上呼吸道感染药茶的制备方法
CN105250968A (zh) 一种治疗哮喘的中药制剂
CN110833615A (zh) 一种用于脐疗治疗慢性鼻炎的中药组合药物及其制备工艺
CN103948827A (zh) 一种围手术期雾化吸入用药物组合物
CN104367975A (zh) 一种止咳祛痰款冬花膏
CN104353045A (zh) 一种具有防治哮喘作用的核桃膏
CN103948810A (zh) 一种开胸手术术前干预药物的制备方法
CN103948826A (zh) 一种围手术期使用的雾化吸入液及其制备方法
CN115300544B (zh) 一种疏风解表、消肿通窍的中药组合物、贴剂及制备方法
CN103920056B (zh) 一种预防手术后气管痉挛的雾化吸入液及其制备方法
CN106983721A (zh) 治疗哮喘的喷雾剂及其制备方法
CN104922279A (zh) 一种治疗慢性鼻炎的外用中药组合物及其制备方法
CN105250614A (zh) 一种喉咳雾化吸入粉制备方法
CN113262289A (zh) 治疗鼻及鼻窦炎的中药组合物、制剂及其制备方法
CN103784633B (zh) 一种治疗小儿鼻炎的中药组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20894708

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20894708

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20894708

Country of ref document: EP

Kind code of ref document: A1